Using (2R,6R)-Hydroxynorketamine to treat neuropathic pain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and duration of analgesia of a single infusion of (2R,6R)-Hydroxynorketamine (HNK) compared to ketamine and saline in patients with chronic neuropathic pain of the extremities. Participants will receive each treatment in a randomized order with a 5-week interval between infusions. The study aims to assess pain intensity, pain qualities, physical function, sleep disturbances, and overall quality of life. Safety assessments and various evaluations will be conducted throughout the study to ensure participant well-being.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (18 to 75 years) with an established diagnosis of chronic (\> 3 month) NP of the extremities.
* Presence of NP as determined at screening using the 10 item Neuropathic Pain Questionnaire (DN4), with a score of ≥4 required for study inclusion.
* Ability to read and write English sufficiently to complete study related procedures.
* A body mass index (BMI) (weight \[kg\]/height\[m \]) between 18 and 35 kg/m (inclusive) and weighs between 50 kg and 120 kg (110 - 264 pounds).
* Blood pressure with subject is in a supine position for approximately 5 minutes between 90 and 145 mmHg systolic and no higher than 90 mmHg diastolic at baseline.
* A 12-lead ECG with no clinically significant abnormality as judged by the Investigator and QTc interval ≤ 450 milliseconds at baseline.
* Resting pulse rate between 45 and 100 beats per minute.
* Clinical laboratory findings and liver function tests within the normal range, or if outside of the normal ranges, deemed not clinically significant in the opinion of the PI.
* Agree to provide written informed consent and comply with the rules regarding consumption of alcohol, caffeinated beverages, and tobacco/nicotine products during the study.
* Patients may be taking scheduled or as needed medications for their chronic neuropathic pain and agree to continue taking the scheduled medications throughout the study period.
* If the subject experiences pain relief they may elect not to take as needed medications.

Exclusion Criteria:

* Subjects with suspected increased intracranial or intraocular pressure.
* Subjects that have previously received ketamine for the treatment of a chronic pain diagnoses.
* Previous or current participation in any clinical study with an investigational drug, device, or biologic within 30 days.
* Subjects with severe medical illness including (but not limited to) hepatic, cardiovascular, pulmonary, renal, hematologic, endocrine, gastrointestinal, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease that in the opinion of the PI would endanger the safety of the subject or the validity of the study results.
* Clinically significant acute illness in the 2 weeks prior to dosing.
* Inability to effectively communicate with research staff.
* Subjects with known liver disease.
* Widespread pain or a diagnosis of fibromyalgia.
* Current diagnosis of mental illness.
* Pregnancy.
* Allergy to ketamine or any study drug.
* Consumption of beverages or food that contain alcohol, grapefruit, poppy seeds, Brussel sprouts, pomegranate, broccoli, char-grilled meat within 2 days prior to drug administration.
* Use of tobacco or nicotine-containing products within 4 weeks prior to drug administration.
* Poor peripheral venous access.
* Subjects in the opinion of the PI should not participate in the study.

Where it's running

• Rush University Medical Center
  Chicago, Illinois, United States Recruiting

Study contacts

• Principal investigator: Asokumar Buvanendran, MD — Rush University Medical Center
• Study coordinator: Robert J McCarthy, Pharm D
• Email: robert_j_mccarthy@rush.edu
• Phone: 3125630448

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VMD-3866 topical gel for chemotherapy-induced nerve pain

  This trial will test whether a non-opioid topical gel called VMD-3866 can reduce pain in adults with chemotherapy-induced peripheral neuropathy.

  Recruiting Phase 2 VM Therapeutics LLC · London, UK · NCT07072468

• Investigating pain mechanisms in patients with spinal cord injuries

  This study is trying to understand how spinal cord injuries cause nerve pain by looking at how the body processes pain and responds to it in people with different types of spinal injuries and nerve issues.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT06443281

• Improving spinal cord stimulation for chronic pain relief

  This study is testing if a new type of spinal cord stimulation can help people with chronic pain feel better compared to the standard method.

  Recruiting Baylor College of Medicine · Houston, Texas · NCT05968664

• Using scrambler therapy to treat pain in corticobasal syndrome

  This study is testing if scrambler therapy can help reduce nerve pain in people with corticobasal syndrome.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT05653778

• Comparing surgical techniques for postamputation pain relief

  This study is testing three different surgical methods to see which one helps people who have had a limb amputated feel less pain in their residual limb, neuroma, and phantom sensations.

  Recruiting Prometei Pain Rehabilitation Center · Chicago, Illinois and 8 other locations · NCT05009394

• Using ozone therapy to treat pain from chemotherapy-induced nerve damage

  This study is testing whether ozone therapy can help cancer patients who have ongoing pain from chemotherapy-induced nerve damage feel better.

  Recruiting at 2 sites Phase 2/3 Hospital Universitario de Gran Canaria Doctor Negrín · Las Palmas de Gran Canaria, Las Palmas and 1 other locations · NCT04299893

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.